All data are based on the daily closing price as of June 6, 2025
s

Sawai Group Holdings

4887.TSE
12.19 USD
-0.12
-0.97%

Overview

Last close
12.19 usd
Market cap
1.41B usd
52 week high
14.62 usd
52 week low
11.30 usd
Target price
17.02 usd

Valuation

P/E
16.6115
Forward P/E
16.7785
Price/Sales
1.0728
Price/Book Value
1.0972
Enterprise Value
1.75B usd
EV/Revenue
1.3377
EV/EBITDA
6.9854

Key financials

Revenue TTM
1.31B usd
Gross Profit TTM
389.06M usd
EBITDA TTM
248.88M usd
Earnings per Share
0.73 usd
Dividend
0.37 usd
Total assets
2.34B usd
Net debt
352.50M usd

About

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
  • Symbol
    4887.TSE
  • Exchange
    TSE
  • Isin
    JP3323040000
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Mitsuo Sawai
  • Headquarter
    Osaka
  • Web site
    https://www.sawaigroup.holdings
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top